Synthesis and anticonvulsive activity of thiolosigamone

European Journal of Medicinal Chemistry

Volumn 33, Issue 7-8, 1998, Pages 665-669

  Schachtner, Josef E ^a   Stachel, Hans Dietrich ^a   Chatterjee, Shyam S ^b   Hauer, Hermann ^b   Polborn, Kurt ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

Aldol reaction; Anticonvulsant; Bioisosterism; Losigamone

Indexed keywords

ANTICONVULSIVE AGENT; LOSIGAMONE;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; PARTITION COEFFICIENT; REACTION ANALYSIS; SEDATION; STRUCTURE ACTIVITY RELATION; X RAY DIFFRACTION;

EID: 0032123638     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(98)80025-1     Document Type: Article

References (24)

1. [1] Hãnsel R., Pelter A., Phytochemistry 10 (1971) 1627-1634.
2. [2] Pelter A., Ayoub M.T., Schultz J., Hänsel R., Reinhardt D., Tetrahedron Lett. (1979) 1627-1630.
3. [3] Achenbach H., Witzke J., Tetrahedron Lett. (1979) 1579-1580.
4. [4] Stachel H.-D., Dandl K., Tetrahedron Lett. (1980) 2891-2892.
5. [5] Pelter A., Al-Bayati R.I.H., Ayoub M.T., Lewis W., Pardassani P., J. Chem. Soc. Perkin Trans, 1 (1987) 717-742.
6. [6] Reinhardt R., Hänsel R., Z. Naturforsch. 32c (1977) 290-291.
7. [7] Khezerlu S., PhD Thesis, Universität Freiburg, 1972.
8. [8] Hänsel R., Beer C., Schulz J., Chem. Ber. 106 (1973) 3119-3126.
9. [9] Chatterjee S.S., Klessing K. (Dr. Willmar Schwabe GmbH & Co.), DE 3615157 (1987) EP 247320 [(1988) Chem. Abstr. 108 (1988) 112212a].
10. See also: Nöldner M., Chatterjee S.S., Drugs of the Future 15 (1990) 995-996 and references cited therein.
11. [10] Klessing K., Chatterjee S.S., Dreidimensionale Struktur und Wirkung. Int. Symp., Schliersee, 2-4 October 1989.
12. [11] Stein U., in: Levy R.H., Mattson R.H., Meldrum B.S. (Ed.), Antiepileptic Drugs, 4th ed., Raven Press, New York, 1995, pp. 1025-1034.
13. [12] (a) Chatterjee S.S., Nöldner M., CNS Drug Reviews, in press.
14. (b) Kohr G., Heinemann U., Epilepsy Res. 7 (1990) 49-58.
15. (c) Schmitz D., Gloveli T., Heinemann U., Neurosci. Lett. 200 (1995) 141-143.
16. (d) Zhang C.L., Chatterjee S.S., Stein U., Heinemann U., Naunyn Schmiedebergs Arch. Pharmacol. 345 (1992) 85-92.
17. [13] Shapiro G., Floersheim P., Boelsterli J., Anstutz R., Bolliger G., Gammenthaler H., Gmelin G., Supavilai P., Walkinshaw M., J. Med. Chem. 35 (1992) 15-27.
18. [14] Schachtner J., Stachel H.-D., Polborn K., Anke T., Eur. J. Med. Chem 33 (1998) 309-319.
19. [15] Stachel H.-D., Schachtner J., Lotter H., Tetrahedron 49 (1993) 4871-4880.
20. [16] Burger A., in: Jucker J. (Ed.), Progress in Drug Research, Vol. 37, Birkhäuser Verlag, Basel, 1991, pp. 287-371.
21. [17] Meul T., Lonza A.G., EP 261-668, Chem. Abstr. 109 (1988) 92768b.
22. [18] Sheldrick G.M., SHELXS-86, Universität Goettingen, 1990.
23. [19] Sheldrick G.M., SHELXL-93, Universität Goettingen, 1993.
24. [20] Zsolnai L., XPMA, ZORTEP, Universität Heidelberg, 1994.